These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
373 related articles for article (PubMed ID: 24018623)
1. Lenalidomide as a disease-modifying agent in patients with del(5q) myelodysplastic syndromes: linking mechanism of action to clinical outcomes. Giagounidis A; Mufti GJ; Fenaux P; Germing U; List A; MacBeth KJ Ann Hematol; 2014 Jan; 93(1):1-11. PubMed ID: 24018623 [TBL] [Abstract][Full Text] [Related]
2. Pleiotropic mechanisms of action of lenalidomide efficacy in del(5q) myelodysplastic syndromes. Heise C; Carter T; Schafer P; Chopra R Expert Rev Anticancer Ther; 2010 Oct; 10(10):1663-72. PubMed ID: 20942636 [TBL] [Abstract][Full Text] [Related]
3. Lenalidomide: Myelodysplastic syndromes with del(5q) and beyond. Talati C; Sallman D; List A Semin Hematol; 2017 Jul; 54(3):159-166. PubMed ID: 28958290 [TBL] [Abstract][Full Text] [Related]
4. Deletion 5q MDS: molecular and therapeutic implications. Komrokji RS; Padron E; Ebert BL; List AF Best Pract Res Clin Haematol; 2013 Dec; 26(4):365-75. PubMed ID: 24507813 [TBL] [Abstract][Full Text] [Related]
5. Lenalidomide for treatment of myelodysplastic syndromes. Komrokji RS; List AF Curr Pharm Des; 2012; 18(22):3198-203. PubMed ID: 22571699 [TBL] [Abstract][Full Text] [Related]
6. Myelodysplastic syndromes with 5q deletion: pathophysiology and role of lenalidomide. Gaballa MR; Besa EC Ann Hematol; 2014 May; 93(5):723-33. PubMed ID: 24627193 [TBL] [Abstract][Full Text] [Related]
7. Lenalidomide for treatment of myelodysplastic syndromes: current status and future directions. Komrokji RS; List AF Hematol Oncol Clin North Am; 2010 Apr; 24(2):377-88. PubMed ID: 20359632 [TBL] [Abstract][Full Text] [Related]
8. Lenalidomide in myelodysplastic syndromes: an erythropoiesis-stimulating agent or more? Komrokji RS; Lancet JE; List AF Curr Hematol Malig Rep; 2010 Jan; 5(1):9-14. PubMed ID: 20425391 [TBL] [Abstract][Full Text] [Related]
9. Lenalidomide inhibits the malignant clone and up-regulates the SPARC gene mapping to the commonly deleted region in 5q- syndrome patients. Pellagatti A; Jädersten M; Forsblom AM; Cattan H; Christensson B; Emanuelsson EK; Merup M; Nilsson L; Samuelsson J; Sander B; Wainscoat JS; Boultwood J; Hellström-Lindberg E Proc Natl Acad Sci U S A; 2007 Jul; 104(27):11406-11. PubMed ID: 17576924 [TBL] [Abstract][Full Text] [Related]
11. Lenalidomide: a review of its use in patients with transfusion-dependent anaemia due to low- or intermediate-1-risk myelodysplastic syndrome associated with 5q chromosome deletion. Syed YY; Scott LJ Drugs; 2013 Jul; 73(11):1183-96. PubMed ID: 23824699 [TBL] [Abstract][Full Text] [Related]
12. Lenalidomide: targeted anemia therapy for myelodysplastic syndromes. List AF; Baker AF; Green S; Bellamy W Cancer Control; 2006 Dec; 13 Suppl():4-11. PubMed ID: 17242661 [TBL] [Abstract][Full Text] [Related]
13. A critical role for phosphatase haplodeficiency in the selective suppression of deletion 5q MDS by lenalidomide. Wei S; Chen X; Rocha K; Epling-Burnette PK; Djeu JY; Liu Q; Byrd J; Sokol L; Lawrence N; Pireddu R; Dewald G; Williams A; Maciejewski J; List A Proc Natl Acad Sci U S A; 2009 Aug; 106(31):12974-9. PubMed ID: 19470455 [TBL] [Abstract][Full Text] [Related]
14. Treatment of Patients With Myelodysplastic Syndrome With Lenalidomide in Clinical Routine in Austria. Aschauer G; Greil R; Linkesch W; Nösslinger T; Stauder R; Burgstaller S; Fiegl M; Fridrik M; Girschikofsky M; Keil F; Petzer A Clin Lymphoma Myeloma Leuk; 2015 Nov; 15(11):e143-9. PubMed ID: 26422252 [TBL] [Abstract][Full Text] [Related]
15. Clinical characteristics and outcomes according to age in lenalidomide-treated patients with RBC transfusion-dependent lower-risk MDS and del(5q). Fenaux P; Giagounidis A; Selleslag D; Beyne-Rauzy O; Mittelman M; Muus P; Nimer SD; Hellström-Lindberg E; Powell BL; Guerci-Bresler A; Sekeres MA; Deeg HJ; Del Cañizo C; Greenberg PL; Shammo JM; Skikne B; Yu X; List AF J Hematol Oncol; 2017 Jun; 10(1):131. PubMed ID: 28651604 [TBL] [Abstract][Full Text] [Related]
16. Clinical management of myelodysplastic syndromes with interstitial deletion of chromosome 5q. Nimer SD J Clin Oncol; 2006 Jun; 24(16):2576-82. PubMed ID: 16735711 [TBL] [Abstract][Full Text] [Related]
17. Clinical effect of increasing doses of lenalidomide in high-risk myelodysplastic syndrome and acute myeloid leukemia with chromosome 5 abnormalities. Möllgård L; Saft L; Treppendahl MB; Dybedal I; Nørgaard JM; Astermark J; Ejerblad E; Garelius H; Dufva IH; Jansson M; Jädersten M; Kjeldsen L; Linder O; Nilsson L; Vestergaard H; Porwit A; Grønbæk K; Hellström-Lindberg E Haematologica; 2011 Jul; 96(7):963-71. PubMed ID: 21719884 [TBL] [Abstract][Full Text] [Related]
18. Lenalidomide--a transforming therapeutic agent in myelodysplastic syndromes. List A Clin Lymphoma Myeloma; 2009; 9 Suppl 3():S302-4. PubMed ID: 19778857 [TBL] [Abstract][Full Text] [Related]
19. Short- and long-term benefits of lenalidomide treatment in patients with lower-risk del(5q) myelodysplastic syndromes. Komrokji RS; List AF Ann Oncol; 2016 Jan; 27(1):62-8. PubMed ID: 26504152 [TBL] [Abstract][Full Text] [Related]
20. High level of full-length cereblon mRNA in lower risk myelodysplastic syndrome with isolated 5q deletion is implicated in the efficacy of lenalidomide. Jonasova A; Bokorova R; Polak J; Vostry M; Kostecka A; Hajkova H; Neuwirtova R; Siskova M; Sponerova D; Cermak J; Mikulenkova D; Cervinek L; Brezinova J; Michalova K; Fuchs O Eur J Haematol; 2015 Jul; 95(1):27-34. PubMed ID: 25284710 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]